Last year, Ranbaxy had paid around $4,20,000 to the US state of Idaho as part of a $500-million settlement that the drug firm had signed with US authorities.
Takeda had filed a case of patent infringement in response to Zydus' abbreviated new drug application.
The Supreme Court on Monday posed some tough questions to a lawyer, asking him to substantiate his "unfounded allegations" in a PIL that Indian pharma major Ranbaxy Laboratories Ltd was allegedly manufacturing and selling adulterated medicines.
Pharma was the top losing index amid worries about their earnings outlook with Lupin down over 4%
Of the 30-share Sensex pack, 22 ended with losses while NTPC ended flat at Rs 127.30.
Sun Pharma's offer was tempting because Ranbaxy was too busy fighting fires in the US to concentrate on operations.
Upset over the Devyani Khobragade episode, India on Wednesday raised with the United States its concerns over "trafficking" visas issued to family members of Sangita Richard, the absconding maid of the Indian diplomat whose arrest had triggered a row between the two countries.
Zuckerberg leads the pack with a net worth of $47.1 billion.
Formal warning to Indian unit of deficiencies noted during inspection at facility near Chennai; firm says will remedy
Money managers have turned cautious about the technology space.
On BSE, 1,469 shares fell and 1,200 shares rose. A total of 190 shares were unchanged.
The company has received a communication from the Medicines and Healthcare Products Regulatory Agency, United Kingdom, whereby the agency has decided to withdraw the previously issued GMP Certificate to the company's manufacturing facility situated at Kadaiya, Nani Daman, Wockhardt said in a filing to the Bombay Stock Exchange.
This is not just a Ranbaxy or Wockhardt problem, says K Satish Reddy
Competition in the US pharmaceutical market swelled in recent years, with increasing generic penetration.
The first drug to treat low sexual desire in premenopausal women, dubbed "female Viagra", has been approved in the United States, but with a warning about potentially dangerous side effects such as severe low blood pressure and fainting.
Roadshows will be held in Singapore, Hong Kong, London, New York and Boston, NTPC gained close to 1%.
The fees for facility inspection of foreign companies have been reduced
4 Ranbaxy facilities in India have been barred from exporting to US.
From scanning hospital entrants to disinfecting hospital areas and floors, robots are being roped in for tasks considered high-risk, says Peerzada Abrar.
Patanjali's packet milk to be lower than competitor brands by Rs 2 a litre
The US Drug maker requested the court to pass an order to restrain DRL from commercially manufacturing, using, offering for sale, selling, marketing, distributing, or importing DRL's generic paricalcitol injectable products prior to the expiration of said patents.
Addressing a press briefing, health ministry Joint Secretary Lav Agarwal said currently there are no approved therapies for COVID-19 and there is not enough evidence to claim that plasma therapy can be used for treatment of the disease.
Broader market outperformed with the S&P BSE Midcap index adding 0.7%, while S&P BSE Smallcap index gained 0.6%.
'The focus for value creation will be on all business segments.'
On her maiden visit to India, US Food and Drug Administrator Margaret A Hamburg has said recent lapses in quality by a handful of pharma companies has overshadowed the good things done by other Indian companies, who emphasise on quality products and practices.
In the longest losing streak of 2017, the BSE Sensex has lost 1,270 points, or 3.91 per cent. It fell to a three-month low of 31,154.03 on Wednesday.
The news that exports to the US will not restart before next year as well as the September quarter performance are sentiment dampeners.
In May this year, Ranbaxy had pleaded guilty to 'felony charges' for violating manufacturing norms and agreed to pay $500 million penalty to US authorities.
Sun Pharma to retain these in most markets; US could be the exception, where the Ranbaxy name has taken a hit.
Midcap stocks continued to remain on buyers' radar with BSE Midcap index up 0.1%.
The company buys distressed assets across the globe and turns them around to not only add to its books but also its product pipeline and regions.
A day after getting a show-cause notice from the Indian regulator, senior executives from Ranbaxy Laboratories approached the drug controller's office on Tuesday afternoon, it was learnt.
CBD oil, found in marijuana, is gaining popularity for its pain-relieving properties. It's now legally available in India
HSBC maintained "overweight" rating on Indian equities, saying "fundamentals are strong".
The winter session of Parliament will commence on November 26.
Analysts say those taking exposure through stocks could look at firms focused on domestic business
TCS, Infosys and Wipro were down 0.4-2% each. Capital goods majors also ended lower with L&T and BHEL down 1.4-3.9% each.
The court also restrained RHC Holdings from operating its bank accounts except for payment of salaries and statutory dues till March 23, the next date of hearing.
India consistently ranked among the top three countries whose products were rejected for import by the regulator.
The move assumes significance because a go-ahead from the US Food and Drug Administration for the new unit in Visakhapatnam is likely to give a huge boost to the company's revenues in upcoming quarters.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances